Publication date: Dec 17, 2024
A multi-centre, randomized, open-label clinical trial. All treatments will be administered orally (PO) on days 1-14. 15 participants will be recruited into each treatment arm in two sequential cohorts. Each cohort will have participants enrolled onto the experimental regimen(s) or the standard of care (SOC; HRZE) control arm. • Cohort 1 aims to generate safety data for a higher dose of alpibectir plus ethionamide 125 mg and 250 mg (arm 1: A45E125 and arm2: A45E250). Once 5 participants have enrolled into arms 1 and 2 each, and completed 14 days of treatment, an interim safety review will be conducted to determine whether the study can advance to cohort 2. • Cohort 2 will investigate safety of alpibectir and ethionamide (A45E250) in combination with rifampicin, pyrazinamide and ethambutol (A45E250RZE). Participants on HRZE will serve as control for the EBA quantitative mycobacteriology in each cohort, and additionally as a safety benchmark for the A45E250RZE arm. The study is not statistically powered to make between arm comparisons of activity or safety. The treatment will not be blinded but the mycobacteriology laboratory staff performing the endpoint assays will remain blinded until analysis of the EBA results.
| Concepts | Keywords |
|---|---|
| A45e125 | Adults |
| Childbearing | Alpibectir |
| Mycobacteriology | Drug- Susceptible |
| Pilot | Ethambutol |
| Ethionamide | |
| Newly Diagnosed | |
| Pulmonary Tuberculosis | |
| Pyrazinamide | |
| Rifampicin |